Innovators Club: Bioconvergence – Unlocking The Potential Of Personalized Medicine
The Bioconvergence revolution is here!
Type of Event
22 Jun 2022
From 17:00 to 18:15 UTC+02:00
Bioconvergence - Unlocking The Potential Of Personalized Medicine
About the Event
The Bioconvergence revolution is here!
By combining digital and material science with biotechnology, this exciting field allows humanity to unlock the full potential of data & digital for a better future of healthcare. Learn more about this groundbreaking megatrend and how it brings disciplines together, transitioning from a siloed perspective towards a new, multi-disciplinary approach that enables scientific discovery.
For example, can you imagine receiving a medical treatment that has been designed exclusively for you, tailored to your own biology? Watch the recording and get insights on how AI-powered drug discovery will affect our lives and how Translational Medicine, Neuromorphic Computing, and Digital Twins will play a key role within this enabling industry segment.
Get inspired by the keynotes “The Bioconvergence revolution is here” and “End to end AI-powered drug discovery and development: From zero to clinic in record time” held by Nina Siragusa, PhD, Technology Chief of Staff at the Science and Technology Office at Merck KGaA, Darmstadt, Germany and Alex Zhavoronkov, PhD, CEO of InSilico Medicine respectively. The keynotes were followed by a fireside chat, welcoming Ravi Kiron, PhD, MBA, Strategic Innovation US at EMD Serono answering questions from the audience. The event was hosted by Annika Zille, from the Group Science and Technology Office of Merck KGaA, Darmstadt, Germany.
Get answers to questions such as:
- Why are we experiencing a Bioconvergence revolution?
- What opportunities does it bring for patients?
- In which fields are our company focused on?
- What hurdles need to be overcome in order for Artificial Intelligence to truly transform the healthcare industry?
About the speakers
PhD, Technology Chief of Staff at the Science and Technology Office of Merck KGaA, Darmstadt, Germany
In her role as Technology Chief of Staff at the Science and Technology Office, Nina Siragusa, PhD is responsible for driving technological advancements by enabling cross-sectoral collaborations within our company. Over the last years, she has held different positions leading and developing early-stage innovation projects at the company´s Innovation Center with a digital core, ultimately driving innovation via global collaboration across Healthcare, Life Science and Electronics business sectors. Nina holds a PhD in biology and advanced her scientific career at the University of Exeter, University of Helsinki, and Yale University.
PhD, Founder and CEO of InSilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of a clinical-stage AI-powered global biotechnology company Insilico Medicine, which raised over $300 million in multiple rounds, nominated 7 preclinical candidates, and entered human clinical trials with an AI-discovered and AI-designed antifibrotic. He is also an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging. Since 2014 he published over 150 peer-reviewed academic publications and two books.
PhD, MBA, Strategic Innovation US at EMD Serono
Ravi Kiron, PhD, based in California, USA, is an experienced pharma/biotech executive with decades of experience in Discovery R&D through late-stage clinical development, intellectual property and regulatory, technology & business development, M&A, strategy, and product commercialization. Currently, he is exploring cutting edge game-changing technologies and establishing strategic partnerships to have an impact on pharma/biotech product development. Dr. Kiron holds a BS in Chemistry, MS in Microbiology from the University of Mumbai, India, a PhD in Biochemistry from the Indian Institute of Science, India, and an MBA from Rensselaer Polytechnic Institute, New York, USA.
The event was hosted by
Head of Marketing, Group Science and Technology Office of Merck KGaA, Darmstadt, Germany